参考文献/References:
[1] Semsarian C,Ingles J,Maron MS,et al. New perspectives on the prevalence of hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2015,65(12):1249-1254.
[2] Nishimura RA,Ommen SR,Tajik AJ. Cardiology patient page. Hypertrophic cardiomyopathy:a patient perspective[J]. Circulation,2003,108(19):e133-e135.
[3] Maron BJ,Rowin EJ,Maron MS. Hypertrophic cardiomyopathy:new concepts and therapies[J]. Annu Rev Med,2022,73:363-375.
[4] Ommen SR,Mital S,Burke MA,et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy:executive summary:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation,2020,142(25):e533-e557.
[5] Weissler-Snir A,Rakowski H,Meyer M. Beta-blockers in non-obstructive hypertrophic cardiomyopathy:time to ease the heart rate restriction?[J]. Eur Heart J,2023,44(37):3655-3657.
[6] Seo K,Yamamoto Y,Kirillova A,et al. Improved cardiac performance and decreased arrhythmia in hypertrophic cardiomyopathy with non-β-blocking R-enantiomer carvedilol[J]. Circulation,2023,148(21):1691-1704.
[7] Arbelo E,Protonotarios A,Gimeno JR,et al. 2023 ESC Guidelines for the management of cardiomyopathies[J]. Eur Heart J,2023,44(37):3503-3626.
[8] Teekakirikul P,Eminaga S,Toka O,et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β[J]. J Clin Invest,2010,120(10):3520-3529.
[9] Ho CY,Day SM,Axelsson A,et al. Valsartan in early-stage hypertrophic cardiomyopathy:a randomized phase 2 trial[J]. Nat Med,2021,27(10):1818-1824.
[10] Vissing CR,Axelsson Raja A,Day SM,et al. Cardiac remodeling in subclinical hypertrophic cardiomyopathy:the VANISH randomized clinical trial[J]. JAMA Cardiol,2023,8(11):1083-1088.
[11] Anderson RL,Trivedi DV,Sarkar SS,et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers[J]. Proc Natl Acad Sci U S A,2018,115(35):E8143-E8152.
[12] Green EM,Wakimoto H,Anderson RL,et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice[J]. Science,2016,351(6273):617-621.
[13] Heitner SB,Jacoby D,Lester SJ,et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy:a clinical trial[J]. Ann Intern Med,2019,170(11):741-748.
[14] Olivotto I,Oreziak A,Barriales-Villa R,et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM):a randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet,2020,396(10253):759-769.
[15] Desai MY,Owens A,Geske JB,et al. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal?Reduction Therapy[J]. J Am Coll Cardiol,2022,80(2):95-108.
[16] Gersh BJ,Maron BJ,Bonow RO,et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation,2011,124(24):2761-2796.
[17] Desai MY,Owens A,Geske JB,et al. Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy:outcomes through 32 weeks[J]. Circulation,2023,147(11):850-863.
[18] Desai MY,Owens A,Wolski K,et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction:week 56 results from the VALOR-HCM randomized clinical trial[J]. JAMA Cardiol,2023,8(10):968-977.
[19] Rader F,Or?ziak A,Choudhury L,et al. Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE Study, EXPLORER-LTE cohort[J]. JACC Heart Fail,2024,12(1):164-177.
[20] Tian Z,Li L,Li X,et al. Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy:the EXPLORER-CN randomized clinical trial[J]. JAMA Cardiol,2023,8(10):957-965.
[21] Wheeler MT,Jacoby D,Elliott PM,et al. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy[J]. Eur J Heart Fail,2023,25(2):260-270.
[22] Tamargo J,Agewall S,Borghi C,et al. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022[J]. Eur Heart J Cardiovasc Pharmacother,2023,9(4):353-370.
[23] Maron MS,Masri A,Choudhury L,et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2023,81(1):34-45.
[24] Owens AT,Masri A,Abraham TP,et al. Aficamten for drug-refractory severe obstructive hypertrophic cardiomyopathy in patients receiving disopyramide:REDWOOD-HCM cohort 3[J]. J Card Fail,2023,29(11):1576-1582.
[25] Coats CJ,Maron MS,Abraham TP,et al. Exercise capacity in patients with?obstructive hypertrophic?cardiomyopathy:SEQUOIA-HCM baseline characteristics and study design[J]. JACC Heart Fail,2024,12(1):199-215.
[26] Gedicke-Hornung C,Behrens-Gawlik V,Reischmann S,et al. Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice[J]. EMBO Mol Med,2013,5(7):1128-1145.
[27] Ma H,Marti-Gutierrez N,Park SW,et al. Correction of a pathogenic gene mutation in human embryos[J]. Nature,2017,548(7668):413-419.
[28] Reichart D,Newby GA,Wakimoto H,et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice[J]. Nat Med,2023,29(2):412-421.
[29] Chai AC,Cui M,Chemello F,et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice[J]. Nat Med,2023,29(2):401-411.
[30] Prondzynski M,Kr?mer E,Laufer SD,et al. Evaluation of MYBPC3 trans-splicing and gene replacement as therapeutic options in human iPSC-derived cardiomyocytes[J]. Mol Ther Nucleic Acids,2017,7:475-486.
相似文献/References:
[1]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(2):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[2]李可 田进文 邓珏琳.老年高血压的临床诊治研究进展[J].心血管病学进展,2019,(9):1208.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.006]
LI Ke,TIAN Jinwen,DENG Juelin.Diagnosis and Treatment in Elderly Hypertension[J].Advances in Cardiovascular Diseases,2019,(2):1208.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.006]
[3]罗芩 何庆.TNF凝集素样结构域：高原肺水肿药物治疗新选择罗芩 何庆2[J].心血管病学进展,2019,(9):1301.[doi:10.16806/j.cnki.issn.1004-3934.2019.00.030]
LUO QinHE Qing.The Lectin-like Domain of TNF:New Drug Treatment Option for HAPE[J].Advances in Cardiovascular Diseases,2019,(2):1301.[doi:10.16806/j.cnki.issn.1004-3934.2019.00.030]
[4]郭岐龙 芦颜美 张玲 张疆华 邢强 祖克拉·吐尔洪 李耀东 周贤惠 汤宝鹏.新疆地区老年慢性心力衰竭住院患者的病因、合并症及药物治疗的多中心回顾性分析[J].心血管病学进展,2020,(4):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
GUO Qilong,LU Yanmei,ZHANG Ling,et al.Etiology, Comorbidity and Drug Treatment of Elderly Inpatients with Chronic Heart Failure in Xinjiang: A Multi-center Retrospective Study[J].Advances in Cardiovascular Diseases,2020,(2):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
[5]布热比古力·阿布力米提 付真彦.乳腺癌药物治疗与心肌损伤[J].心血管病学进展,2020,(8):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
Burebiguli·abulimitiFU Zhenyan.Drug Therapy of Breast Cancer and Assosiated Myocardial Damage[J].Advances in Cardiovascular Diseases,2020,(2):802.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.005]
[6]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(2):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[7]杨鹏辉 李谧.巨大动脉导管未闭治疗研究进展[J].心血管病学进展,2021,(1):68.[doi:10.16806/j.cnki.issn.1004-3934.20.01.000]
YANG Penghui,LI Mi.Treatment of Large Patent Ductus Arteriosus[J].Advances in Cardiovascular Diseases,2021,(2):68.[doi:10.16806/j.cnki.issn.1004-3934.20.01.000]
[8]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(2):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[9]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(2):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
[10]王娟 杨艳敏.肥厚型心肌病发生缺血性卒中的危险因素和管理策略研究进展[J].心血管病学进展,2021,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
WANG Juan,YANG Yanmin.Risk Factors and Management Strategies of Ischemic Stroke in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(2):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
[11]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(2):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]